Clinical Trials Browser

Phase 3 × Recruiting × Locally Advanced or Metastatic Non-squamous NSCLC × Clear all

NCT06735391 2024-12-16

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Phase 3 Recruiting

Locally Advanced or Metastatic Non-squamous NSCLC